Problem

MRI centers are constrained by long scan times, limited scanner capacity, and backlogs that can leave patients waiting weeks for diagnosis. The pain is operational and clinical: slow access increases anxiety, delays interventions for conditions such as stroke or brain tumors, and forces smaller hospitals to choose between expensive high-end scanners and lower-quality imaging. MICSI’s core economic proposition is that software can turn existing equipment into a higher-throughput asset; Graphene Ventures estimates that cutting scan times by up to 50% and doubling daily patient volume could generate approximately $2 million in additional annual revenue per scanner.

The primary use case is head and neuroimaging—especially diffusion and functional MRI, where noise can obscure clinically important signals—at hospitals and imaging centers that need higher-quality scans without replacing their hardware. MICSI is also targeting a larger PET opportunity in Alzheimer’s care, where aging scanners and the need for amyloid imaging can restrict access to new disease-modifying therapies.

Product / Service

MICSI provides imaging software that upgrades existing MRI and PET scanners rather than requiring new scanner hardware. Its FDA-cleared MICSI-RMT product uses the MP-PCA algorithm to exploit redundancy across MRI measurements and remove noise, with additional modules for quantitative diffusion analysis and DICOM routing. In a typical workflow, images move from the scanner through a DICOM router and processor, are denoised, and are returned to the clinical PACS for radiologist review.

The benefit is a combination of higher effective resolution, improved signal-to-noise ratio, fewer required images, shorter examinations, and better utilization of installed equipment. MICSI-RMT is cleared for head-MRI image enhancement and noise reduction, while MICSI-PET applies the company’s physics-based enhancement approach to existing PET scanners to support higher-resolution amyloid and Tau imaging; its FDA submission is complete and awaiting clearance.

Market

MICSI competes in AI-enabled medical-imaging software, spanning MRI denoising, image reconstruction, scan acceleration, and scanner-life extension, with PET enhancement as an adjacent expansion. Relevant competitors include Subtle Medical’s SubtleMR and SubtleHD/ELITE products and AIRS Medical’s SwiftMR, which similarly market vendor-neutral MRI enhancement, denoising, acceleration, and throughput improvements. MICSI’s differentiation is its MP-PCA, physics-based approach and initial focus on diffusion and functional head MRI rather than only generic image sharpening or reconstruction.

The company has progressed beyond a purely pre-product stage: MICSI-RMT received FDA 510(k) clearance in July 2024, and the company’s public materials describe it as in market. The newer MICSI-PET product remains in the commercialization process, with clinical-validation and pilot activity associated with early installs. Public sources reviewed do not disclose revenue, customer counts, or a confirmed installed-base figure, so the evidence supports early commercialization and regulatory traction, but not a claim of mature scale or verified revenue.